This report provides evidence that genetic deletion of mouse VIP receptors results in significant phylogenetic differences (β-diversity) in fecal microbiota compared to wild type controls, irrespective of sex. VPAC1 KO fecal samples, which showed more substantial β-diversity changes compared to VPAC2 KO animals, also showed reductions in richness and α-diversity. Moreover, altered OTUs from VPAC1 fecal samples, including Bacteroides, Parabacteroides, Lactobacillus and Parasutterella, shared significant agreement to altered OTUs from VIP KO samples previously published 19. In total, these data support that VIP receptor deficiency is associated with changes in gut microbiota ecology to different magnitudes and signaling mechanisms, highlighting their importance for gut health and homeostasis.
The influence of VIP within the GIT is dependent on the expression profile of its receptors, VPAC1 and VPAC2. In mice, Jayawardena et al. reported exclusive VPAC1 expression in the jejunum and ileum, with a 300-fold higher mRNA expression level for VPAC1 compared to VPAC2 or VIP’s low-affinity receptor, pituitary adenylyl cyclase activating polypeptide 1 (PAC1) in the proximal and distal colon. Mucosal scrapings of intestinal epithelial cells reveal similar VPAC1 protein expression throughout the mouse intestines 5. Earlier radioactive VIP labeled protein studies and VPAC2-specific binding studies support VPAC1 as the predominant VIP receptor throughout the small and large intestines 28,35. In humans, VPAC1 is also the predominant VIP receptor in sigmoid colon as assessed at the RNA and protein levels, with less but equivalent expression of all three VIP receptors in the small intestines 5. Moreover, human HT-29 and Caco-2 intestinal epithelial cell lines express high levels of functional VPAC1 receptors 36,37. Initial VPAC1 subcellular localization studies suggested a basolateral position for VPAC1 in rat, rabbit and human IECs 38, while a more recent report showed murine VPAC1 expression co-localizing with the apical (e.g. villin), but not basolateral (e.g. Na+/K+ ATPase), IEC marker 30. These different findings could be explained by the heterogenous makeup of IECs consisting of absorptive (e.g. enterocytes and M cells) versus secretory (e.g. Goblet and Tuft) cell types, which are constantly renewed every ≈7 days from differentiating crypt progenitor cells that migrate to the villus 39. Interestingly, VPAC1 can be targeted to the nuclear membrane, which may further alter signaling effects dependent on its subcellular localization (e.g. apical, basolateral and/or nuclear) 40. The present study supports VPAC1 as the predominant intestinal VIP receptor as its genetic deletion manifested in a more substantial change to the fecal microbiota composition compared to WT littermate controls or the VPAC2 colony. Furthermore, altered fecal bacterial taxa from VPAC1 KO mice presented significant similarities to those previously published by our group from VIP KO animals 19, suggesting a bona fide VIP→VPAC1 signaling pathway in IECs regulating the stability and diversity of the gut microbiota.
Intestinal IECs provide physical and chemical barriers that protect the host from the gut microbiota, while absorbing essential nutrients for host survival 41. Breakdown of the intestinal epithelial barrier and gut microbiota dysbiosis are linked to serious health consequences, including inflammatory bowel disease 42, type II diabetes 43 and obesity 44. Evidence linking VIP→VPAC1 signaling to IEC homeostasis and intestinal barrier integrity has been provided by multiple studies. First, observations in the 1980’s demonstrated VIPergic neurons in the intestinal mucosa, showing VIP accumulation in the lumen when stimulated by cholera toxin 45,46. More recent studies have confirmed that VIPergic nerve fibers innervate all layers of the intestinal tissue and account for nearly 50% of enteric neurons 12. Moreover, a 2020 report delineated VIPergic nerves within the intestinal mucosa co-localizing with the β-III-tubulin neuronal marker 30. Second, VIP KO mice possess fewer proliferating, mucin-expressing Goblet cells, compared to WT controls. Morphologically, VIP deficient mice manifested shorter and wider intestinal crypts with impaired barrier function as FITC-dextran enemas demonstrated greater fluorescence in the vasculature compared to control mice. Exogenously added VIP to VIP KO mice partially rescued the above phenotypes, and the authors concluded that the Goblet-specific defect and intesinal barrier ultrastructural changes were unlikely explained by developmental abnormalities 14. Third, Waschek’s group published findings that VIP-deficient mice had morphological defects within the GIT, including shorter, but heavier intestines resembling a “rubbery” appearance, due to a thickening of the muscularis propria. This group also reported a reduced mucus secretion potential from Goblet cells in VIP KO mice, consistent with the above study 12. Fourth, older investigations contribute supportive evidence showing that VIP signaling increases proliferation of IECs from in vivo and in vitro experiments 47,48. Lastly, a report using an organotypic mouse intestinal slice model that maintained three-dimensional intestinal architecture provided evidence that blocking VIP signaling with a pan-VPAC antagonist substantially reduced the number of mucus-producing Goblet cells in intestinal crypts, suggesting that VIP signaling is important for Goblet cell differentiation and survival 49. Couple the above intesinal IEC changes with other known intestinal VIP effects including: 1.) regulation of luminal water and electrolyte levels 50, 2.) peristalsis rate 51, 3.) metabolic gut hormone secretion, 1, 4.) anti-inflammatory effects 14,52,53 and 5.) antimicrobial activity 54, it becomes apparent that there is potential for an amalgamation of environmental changes within the intestines from dysregulated VIP signaling. Genetic ablation of either VIP 19 or VPAC1 (present study) results in significant and similar gut microbiota compositional changes and reduction in microbiota diversity. In aggregate, we propose a neuronal-IEC VIP→VPAC1 signaling circuitry is critical to maintaining intestinal health, goblet cell homeostasis and a stable gut microbiota.
VIP→VPAC1 signaling in IECs maintains the expression of several genes. One of these gene targets is the intestine-specific protein, called caudal-related homeobox transcription factor 2 (CDX2), which is significantly reduced in VIP KO intestinal tissue 14. CDX2 is critical for epithelial progenitor self-renewal and differentiation, and CDX2 conditional knockouts transition to a gastric-like appearance 55. Wu X. et al. showed that VIP KO mice had fewer Goblet cells and abnormally elevated proliferative capacity in cells the closer they were to intestinal crypts, providing evidence that a VIPàCDX2 axis may influence the proliferation/differentiation balance of epithelial progenitors 14. CDX2 transcriptionally activates MUC2 and Tff3, which are major gene products in mucus 56,57. VIP deficient mice show reduced MUC2 expression/secretion in intestine, and MUC2 deficiency leads to a depletion of the butyrate-producing Ruminococcaceae Family as observed in the present study from VPAC1 KO mice, and in VIP KO animals previously published 19. CDX2 also regulates tight junction genes that contribute to intestinal barrier function. During intestinal inflammatory insult either by hypoxia/LPS, TNBS or Citrobacter rodentium infections, endogenously added VIP or a more stable recombinant VIP analogue (rVIPa), results in restored levels and subcellular targeting of tight junction proteins, Claudin-3, occludin and ZO-1 by inhibition of PKC€ and myosin light chain kinase (MLCK) 58-60. These data support a VIP→VPAC1→CDX2→MUC2 pathway in intestinal progenitor cells and Goblet cells that maintains epithelial barrier integrity, mucus secretion, tight junctions and gut microbiota stability. Future research employing VIP receptor conditional knockouts and fate mapping will be instrumental in better understanding this important molecular pathway.
To date, there exists significant disagreement as to whether VIP deficiency results in greater or less susceptibility to intestinal inflammation, including models of IBD 61,62. Our group and others have suggested that genetic deletion of VIP influencing gut microbiota changes, along with other environmental factors such as diet and housing conditions, may tip the scales towards an anti- versus pro-inflammatory intestinal tone 14,19. An additional possibility could be a delicate balance between mutually opposing VIP→VPAC1→CDX2 and NF-κB actions regulating proinflammatory genes. Proinflammatory cytokines (e.g. TNF-α) can increase p50/p65 NF-κB heterodimers that compete away activating p50/p50 NF-κB homodimers at the CDX2 promoter thereby inhibiting its expression. In opposition to this, CDX2 can limit p50/p65 DNA binding and upregulation of proinflammatory genes, while bolstering its own expression 63. VIP→VPAC1 signaling inhibits p50/p65 NF-kB nuclear localization by stabilizing IκB in inflamed intestinal tissue that blocks LPS-induced TNF-α that in turn would maintain CDX2 expression 59,64. Consistent with this mechanism, human IBD tissue samples show reduced VIPergic nerve density and CDX2 expression, with elevated NF-kB p50/p65 activation 65,66. Furthermore, CDX2 heterozygous mice are more susceptible to DSS induced colitis compared to controls 67. CDX2’s transcriptional activity regulating genes that control barrier integrity, cellular differentiation and apoptosis are regulated in turn by MAP kinases. Phosphorylation of CDX2 on serine 60 by ERK1/2 decreases its transcriptional activity, while phosphorylation by p38 increases its transcriptional activity. VIP→VPAC1 signaling could switch CDX2 from transcriptionally active to transcriptionally repressive through its ability to activate both ERK1/2 and p38 pathways. Disentangling the VIP→VPAC1→CDX2 and NF-κB signaling circuitry in IECs will be critical in better understanding the intricate balance between intestinal barrier integrity, inflammation and gut bacterial ecology.
Both VPAC1 and VPAC2 are expressed by various immune cells within the intestines, including macrophages and T cells 68. In T cells, VPAC1 has been reported by our group and others to be expressed at higher levels than VPAC2 in naïve T lymphocytes, but downregulated during T cell activation 69. Vomhoff-DeKrey et al. went further to describe the plasticity of VPAC1 expression returning to naïve levels in antigen-specific CD8 T cell (OT-I transgenic) primary memory cells, that failed to return to naïve levels after a secondary activation using a Th1 pathogen in vivo infection model 3. VIP→VPAC1 signaling can induce tolerogenic dendritic cells, which present commensal peptides to naïve T cells controlling T cell effector/regulator ratios, important in mucosal immunity 52. It has been shown that differences in commensal peptide antigen presentation to T cells within the “mucosal firewall” can have profound influences on gut microbiota composition 20,70. On the other hand, VPAC2 expression is upregulated, while VPAC1 is downregulated on Th2 effector cells, thereby altering how VIP signals are interpreted by T lymphocytes based on their activation status 71. Another immune cell population that expresses VPAC2 and plays a pivotal role in maintaining epithelial barrier integrity is type-3 innate lymphoid cells (ILC3). Microbiota-associated molecular patterns activate dendritic cells and macrophages to produce IL-23, which binds to receptors on CCR6+ ILC3 to secrete IL-22. IEC respond to ILC3-derived IL-22 by secreting the anti-microbial peptide, Reg3g into the lumen, while blocking lipid transporter gene, Fabp2. In 2020, Talbot et al. eloquently demonstrated that food intake and/or Citrobacter rodentium oral gavage resulted in barrier integrity breakdown with greater bacterial translocation to the spleen and liver in a VIP-dependent manner 30. This study showed that VPAC2 crosslinking by VIP on ILC3 caused IL-22 inhibition that simultaneously reduced Reg3g downregulation while increasing the expression of Fabp2. Consistent with the present study, VPAC2 conditional KO mice in ILC3 showed fluctuations in fecal and cecum microbiota composition 30.
VIP shares 68% amino acid identity with pituitary adenylate cyclase activating polypeptide (PACAP), which also binds to both VPAC1 and VPAC2 receptors with similar affinity to VIP (≈1 nM Kd). Both neuropeptides are delivered to the GIT by the peripheral nervous system and PACAP deficient mice also revealed similar fecal microbiota changes with respect to enrichments in Gram negative bacteria, including genera from Bacteroidetes and Proteobacteria72. In contrast, VIP and VPAC1 deficient mice showed similar reductions in the Gram positive Lachnospiraceae and Ruminococcaceae families that were not observed from PACAP knockout mice. Based on the high extent of agreement between VIP- and VPAC1-deficient fecal microbiota compositional changes, and a lack of effect on the Firmicutes phylum reported for PACAP deficient mice, we conclude that there is little to no compensation from PACAP on microbiota composition in either VIP- or VPAC1-deficient mice. We would further posit that these reports bolster the notion of a VIP→VPAC1 signaling axis within the gut that plays a pivotal role in maintaining the stability and diversity of the gut microbiota.
It is difficult to extrapolate the consequence to the host due to the gut microbiota changes observed in VIP receptor deficient mice. However, this report supports a consistency in gut microbiota structural changes between VPAC1 deficient mice (current report) and VIP deficient mice 19. Consistent blooms and depletions at the OTU level were observed that favor LPS positive, Gram-negative (e.g. Bacteroides, Parabacteroides, Parasutterella and Escherichia) bacteria that would be expected to result in inflammation. VIP signaling through VPAC1 has historically been viewed to drive most of the anti-inflammatory effects observed by VIP 73, and with the recent finding that VIP signaling blocks LPS-induced inflammasome formation, we propose that the loss of VIP→VPAC1 signaling provides an environment for elevated LPS from Gram-negative blooms leading to local and possibly systemic inflammation. Research is now ongoing in our research group to assess this possibility.
We have provided 16S rRNA sequencing data from both VPAC1 and VPAC2 KO fecal samples demonstrating statistically significant gut bacterial compositional changes. VPAC1 signaling, presumably in IECs, resulted in more severe alterations in gut microbiota structure and diversity loss compared to VPAC2 deficient mice. Moreover, more than 86% of the gut microbiota genera changes were consistent between VPAC1 deficient samples (present study) and VIP deficient samples (previously published) implicating the VIP→VPAC1 signaling pathway as a major driving force behind gut microbiota stability. Our results place the VIP receptors as pivotal signaling GPCRs regulating intestinal homeostasis and gut microbiota stability. Future research will undoubtably shed greater light on this important signaling axis within the GIT.